Found: 38
Select item for more details and to access through your institution.
Satellite DNA is transcribed on lampbrush chromosomes.
- Published in:
- Nature, 1980, v. 283, n. 5748, p. 686, doi. 10.1038/283686a0
- By:
- Publication type:
- Article
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes.
- Published in:
- International Journal of Laboratory Hematology, 2021, v. 43, n. 3, p. 426, doi. 10.1111/ijlh.13400
- By:
- Publication type:
- Article
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 3, p. 384, doi. 10.1111/bjh.13832
- By:
- Publication type:
- Article
Pevonedistat ( MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 4, p. 534, doi. 10.1111/bjh.13323
- By:
- Publication type:
- Article
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 1, p. 62, doi. 10.1111/bjh.13008
- By:
- Publication type:
- Article
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 3, p. 352, doi. 10.1111/bjh.12884
- By:
- Publication type:
- Article
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.
- Published in:
- Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1
- By:
- Publication type:
- Article
Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2022, v. 25, n. 1, p. 56
- By:
- Publication type:
- Article
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia.
- Published in:
- PLoS ONE, 2014, v. 9, n. 10, p. 1, doi. 10.1371/journal.pone.0108694
- By:
- Publication type:
- Article
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.
- Published in:
- Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00461-0
- By:
- Publication type:
- Article
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
- Published in:
- 2020
- By:
- Publication type:
- journal article
194 Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines.
- Published in:
- American Journal of Clinical Pathology, 2018, v. 149, p. S82, doi. 10.1093/ajcp/aqx121.193
- By:
- Publication type:
- Article
Downward Platelet Utilization Trends in Acute Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1023, doi. 10.1007/s10637-013-9935-x
- By:
- Publication type:
- Article
MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S346, doi. 10.1016/S2152-2650(21)01805-X
- By:
- Publication type:
- Article
Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01451-8
- By:
- Publication type:
- Article
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S220, doi. 10.1016/j.clml.2019.07.094
- By:
- Publication type:
- Article
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S204, doi. 10.1016/j.clml.2018.07.057
- By:
- Publication type:
- Article
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S286, doi. 10.1016/j.clml.2017.07.071
- By:
- Publication type:
- Article
Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S288, doi. 10.1016/j.clml.2017.07.074
- By:
- Publication type:
- Article
Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S63, doi. 10.1016/j.clml.2016.07.091
- By:
- Publication type:
- Article
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- Correction Notice
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
- Published in:
- PLoS ONE, 2016, v. 11, n. 12, p. 1, doi. 10.1371/journal.pone.0166891
- By:
- Publication type:
- Article
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Institutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropenia.
- Published in:
- Pharmacotherapy, 2007, v. 27, n. 7, p. 970, doi. 10.1592/phco.27.7.970
- By:
- Publication type:
- Article
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 4, p. 743, doi. 10.1002/hon.3159
- By:
- Publication type:
- Article
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. E49, doi. 10.1002/ajh.24980
- By:
- Publication type:
- Article
Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 3, p. 242, doi. 10.1002/ajh.23902
- By:
- Publication type:
- Article
Improving Frontline Treatment for Chronic Myeloid Leukemia: Emerging Evidence for Use of Nilotinib and Dasatinib.
- Published in:
- Clinical Advances in Hematology & Oncology, 2011, v. 9, n. 10, p. 734
- By:
- Publication type:
- Article
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 6, p. 1253, doi. 10.1002/cncr.25686
- By:
- Publication type:
- Article
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 1, p. 48, doi. 10.1111/j.1365-2141.2009.07919.x
- By:
- Publication type:
- Article
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.
- Published in:
- 2017
- By:
- Publication type:
- journal article